Lifeward Ltd.
No SEC Form 4 filings for $LFWD in the last 30 days.
See all $LFWD insider activity →Lifeward Ltd. (NASDAQ: LFWD) said it will release its Q2 2026 financial results on Friday, Aug. 14, via a press release and an SEC quarterly report filed before 9:30 a.m. ET. The company highlighted its neurorehabilitation products and its Protein Oral Delivery platform, including ORMD-0801 oral insulin.
Lifeward Ltd. (Nasdaq: LFWD) said it entered a securities purchase agreement for strategic financing with institutional investors. The initial July 6 closing provides about $5.6M in senior secured convertible notes and warrants, with up to another $5.6M tied to milestones: 150% ReWalk unit sales growth or shares at/above $13.80 for 10 days.
Lifeward Ltd. (LFWD) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 7 exhibit_10-1.htm EXHIBIT 10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of June 30, 2026, among Lifeward Ltd., a company organized under the laws of the State of Israel (the “ Company ”), each purchase
Over the past 7 days, alphai's AI scored 1 news story mentioning LFWD (Lifeward Ltd.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent LFWD coverage spans financial news, corporate actions and earnings.
The article is a scheduled earnings timing update, which can drive pre-earnings positioning and volatility into Aug. 14.
The financing provides near-term runway but introduces dilution/convertible overhang; milestone triggers link future funding to ReWalk sales and share-price performance.
The filing signals a new capital raise via convertible notes/warrants, which can pressure equity via dilution and overhang while also funding operations.
The deal provides near-term cash and creates a clear, milestone-linked catalyst that can influence trading around unit sales and the $13.80 level.
LFWD operational progress cited in the letter can be supportive, but it is not a new LFWD earnings release within the article.
alphai scores every news story that mentions LFWD with an AI model for sentiment and relevance, and aggregates insider trades from Lifeward Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Lifeward Ltd. (NASDAQ: LFWD) said it will release its Q2 2026 financial results on Friday, Aug. 14, via a press release and an SEC quarterly report filed before 9:30 a.m. ET. The company highlighted its neurorehabilitation products and its Protein Oral Delivery platform, including ORMD-0801 oral insulin.
1 min readLifeward Ltd. (Nasdaq: LFWD) said it entered a securities purchase agreement for strategic financing with institutional investors. The initial July 6 closing provides about $5.6M in senior secured convertible notes and warrants, with up to another $5.6M tied to milestones: 150% ReWalk unit sales growth or shares at/above $13.80 for 10 days.
4 min readLifeward Ltd. (LFWD) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 7 exhibit_10-1.htm EXHIBIT 10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of June 30, 2026, among Lifeward Ltd., a company organized under the laws of the State of Israel (the “ Company ”), each purchase
3 min readLifeward Ltd. (NASDAQ:LFWD) shares rose 5.6% after hours after the company said it raised $5.6M via senior secured convertible notes and warrants, with another $5.6M available upon milestones: a 150% increase in ReWalk unit sales or shares trading at/above $13.80 for 10 straight days. Lifeward links the financing to a strategic framework with Oramed (NASDAQ:ORMP).
3 min readOramed Pharmaceuticals said in a shareholder letter it will be added to the Russell 2000 and Russell 3000 indexes effective June 29, 2026. The company reported its Alpha Tau (DRTS) position is up about $128 million to ~$167 million (incl. warrants), and that its Scilex (SCLX) $99.5 million loan has been substantially repaid, with ~$43 million expected by Oct. 2026. Oramed also cited total cash and assets of about $270 million as of March 31, 2026.
6 min readRecord quarter of ReWalk systems placed for Medicare beneficiaries since fee schedule established Ongoing efficiency initiatives drive 16% year-over-year decrease in quarterly cash burn and 27% decrease in quarterly Non-GAAP operating loss
3 min readMARLBOROUGH, Mass. and YOKNEAM ILLIT, Sept. 08, 2025 ( GLOBE NEWSWIRE ) -- Lifeward Ltd., LFWD ( "Lifeward" or the "Company" ) , a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, announced today that the company has ...
3 min readLifeward (LFWD) delivered earnings and revenue surprises of -132.00% and -11.53%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
2 min readMARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- Lifeward Ltd.
2 min readMARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- Lifeward Ltd.
2 min read
